Want to see HK:2161 full AI Analyst Report?
2161 Stock Chart & Stats
HK$1.89
HK$0.00(0.00%)
At close: 4:00 PM EDT
HK$1.89
HK$0.00(0.00%)
Day’s Range― - ―
52-Week RangeHK$1.64 - HK$3.11
Previous CloseN/A
Volume140.00K
Average Volume (3M)252.00K
Market Cap
HK$1.35B
Enterprise ValueHK$2.49K
Total Cash (Recent Filing)HK$119.94M
Total Debt (Recent Filing)HK$393.72M
Price to Earnings (P/E)6.6
Beta0.22
Next Earnings
Nov 20, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield10.39%
Share Statistics
EPS (TTM)0.25
Shares Outstanding822,000,000
10 Day Avg. Volume272,508
30 Day Avg. Volume252,003
Financial Highlights & Ratios
PEG Ratio2.55
Price to Book (P/B)2.01
Price to Sales (P/S)2.60
P/FCF Ratio18.20
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.26
Revenue Forecast (FY)HK$880.50M
Bulls Say, Bears Say
Bulls Say
Revenue ScaleRevenue more than doubled across the reported period, demonstrating substantial business expansion and stronger scale. This broader revenue base can support operating leverage, reinforce market presence, and provide a larger platform for continued growth over the next several quarters.
Margin ExpansionThe sharp improvement in gross and net margins shows that growth has translated into materially stronger profitability, not merely higher sales. Improved earnings quality can strengthen internal funding capacity and support reinvestment while enhancing resilience through the medium term.
Profitability And Equity BaseA sizable equity base provides meaningful support for the capital structure, while the rise in return on equity indicates better use of shareholder capital. Together, these factors suggest improved capital efficiency and a stronger foundation for sustaining profitable operations.
Bears Say
Higher LeverageThe increase in debt after relatively low leverage in 2024 and 2025 reduces financial flexibility compared with the prior two years. Higher borrowing can constrain future capital allocation and make the company more sensitive to operating or financing pressures.
Free Cash Flow DeclineAlthough cash generation remained positive, the substantial year-over-year decline in free cash flow weakens the latest cash conversion trend. Less internally generated cash could reduce flexibility for reinvestment, debt management, and other longer-term corporate priorities.
Recent Margin NormalizationThe modest margin easing in 2026 indicates that the earlier profitability expansion may be normalizing at the latest period. If sustained, slower margin progression could limit earnings growth even while revenue continues to expand materially.
JBM (Healthcare) Ltd. News
2161 FAQ
What was JBM (Healthcare) Ltd.’s price range in the past 12 months?
JBM (Healthcare) Ltd. lowest stock price was HK$1.64 and its highest was HK$3.11 in the past 12 months.
What is JBM (Healthcare) Ltd.’s market cap?
JBM (Healthcare) Ltd.’s market cap is HK$1.35B.
When is JBM (Healthcare) Ltd.’s upcoming earnings report date?
JBM (Healthcare) Ltd.’s upcoming earnings report date is Nov 20, 2026 which is in 59 days.
How were JBM (Healthcare) Ltd.’s earnings last quarter?
JBM (Healthcare) Ltd. released its earnings results on Jun 22, 2026. The company reported HK$0.106 earnings per share for the quarter.
Is JBM (Healthcare) Ltd. overvalued?
According to Wall Street analysts JBM (Healthcare) Ltd.’s price is currently Overvalued.
Does JBM (Healthcare) Ltd. pay dividends?
JBM (Healthcare) Ltd. pays a Semiannually dividend of HK$0.073 which represents an annual dividend yield of 10.39%. See more information on JBM (Healthcare) Ltd. dividends here
What is JBM (Healthcare) Ltd.’s EPS estimate?
JBM (Healthcare) Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does JBM (Healthcare) Ltd. have?
JBM (Healthcare) Ltd. has 822,000,000 shares outstanding.
What happened to JBM (Healthcare) Ltd.’s price movement after its last earnings report?
JBM (Healthcare) Ltd. reported an EPS of HK$0.106 in its last earnings report. Following the earnings report the stock price went down -0.409%.
Which hedge fund is a major shareholder of JBM (Healthcare) Ltd.?
Currently, no hedge funds are holding shares in HK:2161
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
JBM (Healthcare) Ltd. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-42.74%
12-Months-Change
Fundamentals
Return on Equity
10.39%
Trailing 12-Months
Asset Growth
14.08%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
JBM (Healthcare) Ltd.
JBM (Healthcare) Limited functions as an investment holding company that operates across Asia, engaging in the entire process of bringing healthcare and wellness products to market, from their conception and production to their promotion, distribution, and ultimate sale. The firm's offerings include a diverse range of consumer health products, such as its own branded traditional Chinese medicines – spanning everything from over-the-counter medications to specific medicated and non-medicated treatments. Additionally, it supplies diagnostic equipment and various pharmaceutical goods. Beyond manufacturing, JBM (Healthcare) is also involved in the buying, selling, and reselling (wholesale and retail) of Chinese medicines. Its business activities extend to the trade of medical supplies and pharmaceuticals, as well as the sale of general health and herbal products. Established in 2020, the company's main operations are directed from its headquarters in Kwun Tong, Hong Kong. JBM (Healthcare) Limited is a subsidiary entity of JBM Group (BVI) Limited.
Technical Analysis
Lee's Pharmaceutical Holdings Limited
―
Dawnrays Pharmaceutical Holdings Ltd.
―
Pak Fah Yeow International Limited
―
Jacobson Pharma Corporation Limited
―
VISEN Pharmaceuticals
―